Kenvue Inc

Kenvue Inc

KVUE

Get informed when a big investor buys or sells

+ Follow
Market Cap$34.79B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Kenvue IncKenvue Inc21.44.58%8%2.60.8

Earnings Call Q2 2025

August 7, 2025 - AI Summary

Top Line Performance Decline: Kenvue reported a 4.2% decline in organic sales for Q2 2025, which was below expectations. The sales drop was attributed to soft seasonal demand in allergy and sun care categories, particularly in the U.S. market, and a disconnect between consumer consumption trends and sales performance. Global consumption grew year-over-year, indicating potential for brand improvement despite sales challenges.
Revised 2025 Outlook: The company has revised its its guidance for 2025, now expecting organic sales to decline in the low single digits. Operating margins are projected to contract due to strategic price investments, fixed cost deleverage, and inflationary challenges, with an adjusted diluted EPS forecast range of $1.00 to $1.05.
Leadership Transition and Strategic Review: Kenvue is undergoing a leadership transition with Kirk Perry stepping in as interim CEO and Amit Banati as the new CFO. The Board has initiated a comprehensive review of strategic alternatives with the goal of optimizing the company's brand portfolio and unlocking shareholder value. Initial observations suggest a need to streamline operations to reduce complexity.

Exclusive for Stockcircle Pro members

Sign upSign Up
$18.00

Target Price by Analysts

2.2% downsideKenvue Target Price DetailsTarget Price
$46.78

Current Fair Value

154.1% upside

Undervalued by 154.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$34.79 Billion
Enterprise Value$42.47 Billion
Dividend Yield$0.83 (4.58%)
Earnings per Share$0.77
Beta0.5
Outstanding Shares1,918,000,000

Return

Return on Equity8.30%ROE
Return on Assets3.28%
Return on Invested Capital13.74%

Valuation & Multiples

P/E Ratio21.43P/E Ratio
PEG45.39PEG
Price to Sales2.63Price to Sales
Price to Book Ratio3.68Price to Book Ratio
Enterprise Value to Revenue2.78
Enterprise Value to EBIT14.75
Enterprise Value to Net Income48
Total Debt to Enterprise0.21
Debt to Equity0.83Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 14, 2026
EPS Estimate
$0.27
Average shareholder expectation
Revenue Estimate
$3.84 B
Average shareholder expectation

Next Earnings Call

Expected Date
August 6, 2026
EPS Estimate
$0.32
Average shareholder expectation
Revenue Estimate
$3.96 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3711 23.61%
Total Calls18,257,600 60.35%
Total Puts6,775,200 75.77%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %90.54% 4.02%
Total Invested$29.91B 4.38%
Investors Holding1,045 61.00%

ESG Score

No data

About Kenvue Inc

Relevant Senate Committees

Joint Committee on Taxation

Provides critical analysis and 'revenue estimates' for tax legislation, directly influencing corporate tax structures and the overall tax burden on Kenvue.

Finance

Controls taxation and trade policy, which directly impact Kenvue's corporate profitability, supply chain costs, and international market access.

Health, Education, Labor, and Pensions

Directly regulates the FDA, a primary oversight body for Kenvue's over-the-counter drugs, cosmetics, and other consumer health products, and influences labor laws affecting its workforce.

Judiciary

Oversees antitrust laws, crucial for large corporations regarding mergers, acquisitions, and market dominance, and intellectual property protection, vital for Kenvue's brands and product formulations.

Commerce, Science, and Transportation

Has vast jurisdiction over interstate commerce and oversees the FTC, which directly regulates advertising, marketing, and competition for consumer health products like Kenvue's.